Allurion

Non-surgical weight loss balloon solutions

Natick, Massachusetts, United States

About Allurion

Allurion focuses on managing obesity through its unique weight loss solution. The Allurion Balloon is a non-surgical weight loss balloon that can be placed and removed without the need for surgery, endoscopy, or anesthesia. This product is part of the Allurion Program, which includes digital tools like the Allurion Mobile App, Allurion Insights for clinicians, and connected devices such as a scale and health tracker. This combination allows patients and healthcare providers to effectively monitor and manage weight loss. Allurion differentiates itself from competitors by offering a comprehensive program that integrates both the balloon and digital health tools, providing ongoing support for users. The company's goal is to help individuals struggling with obesity achieve sustainable weight loss in a safe and effective manner.

Natick, MassachusettsHeadquarters
2009Year Founded
$112.4MTotal Funding
POST_IPO_EQUITYCompany Stage
Consumer Software, HealthcareIndustries
201-500Employees

Benefits

Paid Vacation
Remote Work Options
Phone/Internet Stipend
Professional Development Budget

Risks

Allurion Balloon lacks U.S. approval, limiting market expansion and revenue potential.
Reliance on digital tools faces competition from evolving technology and digital health solutions.
Debt financing reliance poses risks if revenue growth doesn't meet expectations.

Differentiation

Allurion Balloon offers non-surgical weight loss without endoscopy or anesthesia.
Comprehensive digital tools support weight loss, enhancing patient and provider engagement.
Global market reach with innovative, non-invasive obesity management solutions.

Upsides

$48M financing reduces interest expenses, extends debt maturity, and boosts financial stability.
Launch of Virtual Care Suite in the U.S. strengthens market presence and support.
Experienced executives like Keith Johns enhance leadership and international strategies.

Funding

Total raised$112.35 M
Latest valuation$170.00 M
StagePOST_IPO_EQUITY
POST IPO EQUITY
5/31/2024
$20
$863
$27
$135.00 M
LATE VC
1/31/2017
$19
$95.00 M